MGTX (MeiraGTx Holdings plc Ordinary Shares)
Insider Trading Activity
Every open-market purchase and sale reported by MGTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-18 | Alexandria Forbes | PRESIDENT & CEO | Sell | — | — |
| 2026-07-21 | Richard Giroux | CFO & COO | Sell | — | — |
| 2026-07-07 | Stuart Naylor | CHIEF SCI OFCR, OPHTHALMOLOGY | Sell | — | — |
| 2026-06-29 | Robert J Wollin | GENERAL COUNSEL AND SECRETARY | A | — | — |
| 2026-06-29 | Alexandria Forbes | PRESIDENT & CEO | A | — | — |
| 2026-06-29 | Robert K Zeldin | CHIEF MEDICAL OFFICER | A | — | — |
| 2026-06-29 | Richard Giroux | CFO & COO | A | — | — |
| 2026-06-29 | Stuart Naylor | CHIEF SCI OFCR, OPHTHALMOLOGY | A | — | — |
| 2026-06-15 | Keith R. Harris | Director | A | — | — |
| 2026-06-15 | Neil Mendoza | Director | A | — | — |
| 2026-06-15 | Nicole Seligman | Director | A | — | — |
| 2026-06-15 | Ellen Hukkelhoven | Director | A | — | — |
| 2026-06-15 | Debra Yu | Director | A | — | — |
| 2026-06-15 | PERCEPTIVE ADVISORS LLC | Director | A | — | — |
| 2026-06-15 | THOMAS E SHENK | Director | A | — | — |
| 2026-06-10 | Keith R. Harris | Director | M | — | — |
| 2026-05-28 | Richard Giroux | CFO & COO | G | — | — |
| 2026-05-19 | Alexandria Forbes | PRESIDENT & CEO | Sell | — | — |
| 2026-05-14 | Penny Renee Fleck | CHIEF DEVELOPMENT OFFICER | A | — | — |
| 2026-04-28 | Robert K Zeldin | CHIEF MEDICAL OFFICER | F | — | — |
| 2026-04-23 | PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | Director | A | — | — |
| 2026-04-21 | Richard Giroux | CFO & COO | Sell | — | — |
| 2026-04-07 | Stuart Naylor | CHIEF DEV. OFFICER | Sell | — | — |
| 2026-03-24 | Alexandria Forbes | PRESIDENT & CEO | Sell | — | — |
| 2026-02-23 | Robert K Zeldin | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2026-02-23 | Stuart Naylor | CHIEF DEV. OFFICER | MIXED | — | — |
| 2026-02-23 | Richard Giroux | CFO & COO | MIXED | — | — |
| 2026-02-23 | Robert J Wollin | GENERAL COUNSEL AND SECRETARY | MIXED | — | — |
| 2026-02-23 | Alexandria Forbes | PRESIDENT & CEO | MIXED | — | — |
| 2026-01-21 | Stuart Naylor | CHIEF DEV. OFFICER | MIXED | — | — |
| 2026-01-21 | Richard Giroux | CFO & COO | MIXED | — | — |
| 2026-01-21 | Alexandria Forbes | PRESIDENT & CEO | MIXED | — | — |
| 2026-01-21 | Robert J Wollin | GENERAL COUNSEL AND SECRETARY | MIXED | — | — |
| 2026-01-21 | Robert K Zeldin | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2026-01-08 | Robert J Wollin | GENERAL COUNSEL AND SECRETARY | MIXED | — | — |
| 2026-01-08 | Robert K Zeldin | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2026-01-08 | Stuart Naylor | CHIEF DEV. OFFICER | MIXED | — | — |
| 2026-01-08 | Alexandria Forbes | PRESIDENT & CEO | MIXED | — | — |
| 2026-01-08 | Richard Giroux | CFO & COO | MIXED | — | — |
| 2026-01-02 | PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | Director | D | — | — |
| 2025-12-23 | Alexandria Forbes | PRESIDENT & CEO | G | — | — |
| 2025-11-24 | Robert J Wollin | GENERAL COUNSEL AND SECRETARY | G | — | — |
| 2025-10-21 | Richard Giroux | CFO & COO | Sell | — | — |
| 2025-10-07 | Alexandria Forbes | PRESIDENT & CEO | Sell | — | — |
| 2025-07-22 | Richard Giroux | CFO & COO | Sell | — | — |
| 2025-07-08 | Alexandria Forbes | PRESIDENT & CEO | Sell | — | — |
| 2025-07-02 | Richard Giroux | CFO & COO | G | — | — |
| 2025-06-16 | THOMAS E SHENK | Director | A | — | — |
| 2025-06-16 | Keith R. Harris | Director | A | — | — |
| 2025-06-16 | Ellen Hukkelhoven | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 12,531,103 | — |
| — | Director | 11,281,103 | — |
| — | Director | 10,786,658 | — |
| — | Director | 1,995,608 | — |
| — | PRESIDENT & CEO | 1,354,680 | — |
| — | CFO & COO | 993,530 | — |
| — | CHIEF SCI OFCR, OPHTHALMOLOGY | 640,846 | — |
| — | Director | 200,000 | — |
| — | Director | 157,476 | — |
| — | CHIEF MEDICAL OFFICER | 146,204 | — |
| — | GENERAL COUNSEL AND SECRETARY | 57,377 | — |
| — | Director | 35,000 | — |
| — | Director | 5,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MGTX quote page; the site-wide leaderboard is on the insider transactions hub.